Valneva Partners with CSL Seqirus for Vaccine Distribution
Valneva SE, a renowned specialty vaccine company, has taken a significant step toward expanding its market presence by entering into an exclusive agreement with CSL Seqirus. This partnership marks a notable milestone for Valneva as it aims to enhance the marketing and distribution of its innovative vaccines across Germany.
Details of the Marketing Agreement
As part of this new arrangement, CSL Seqirus will manage the commercialization of Valneva’s single-dose chikungunya vaccine IXCHIQ, which is set to launch in the middle of 2025. Additionally, the Japanese Encephalitis vaccine IXIARO, alongside the cholera/ETEC vaccine DUKORAL, are expected to roll out starting January 2026. This collaboration supersedes a previous agreement Valneva had with Bavarian Nordic, which is set to conclude in late December 2025.
Agreement Duration and Conditions
The agreement with CSL Seqirus extends for a period of three years, incorporating minimum annual purchasing commitments and standard termination clauses based on changes in control or performance metrics. This strategic partnership is designed not only to enhance Valneva's distribution capabilities in Germany but also to ensure an uninterrupted supply of products within Europe’s largest travel vaccine market.
Valneva's Expanding Business and Financial Outlook
Dipal Patel, Chief Commercial Officer at Valneva, expressed enthusiasm about the partnership, highlighting that CSL Seqirus's robust commercial infrastructure will synergize with Valneva’s existing efforts. This collaboration is expected to drive sales growth in the crucial German market, benefiting from Valneva's targeted distribution strategies.
In the first quarter of 2025, Valneva recorded impressive product sales of €48.6 million, predominantly attributed to its proprietary vaccines, which accounted for €42.8 million. Looking ahead, the company anticipates total product sales to reach between €170 and €180 million by the end of 2025. This growth trajectory is projected to foster positive cash flows and support the overall sustainability of Valneva's commercial operations.
About Valneva SE
Valneva SE is dedicated to addressing unmet medical needs with a focus on developing, manufacturing, and commercializing vaccines for infectious diseases. Known for its highly specialized approach, Valneva invests in advanced vaccine modalities to provide exceptional solutions that fulfill crucial healthcare gaps. The company has successfully brought multiple vaccines through early research and development phases to approval, currently marketing three proprietary travel vaccines.
Valneva also prides itself on a strong pipeline, which includes the first Lyme disease vaccine candidate in advanced clinical development, alongside candidates targeting the Zika virus and Shigella, reinforcing its commitment to global public health.
Media and Investor Relations
Laetitia Bachelot-Fontaine, VP Global Communications & European Investor Relations, is available for inquiries at +33 (0)6 4516 7099, or via email at laetitia.bachelot-fontaine@valneva.com. For investment-related questions, Joshua Drumm, Ph.D., VP Global Investor Relations, can be contacted at +001 917 815 4520 or joshua.drumm@valneva.com.
Frequently Asked Questions
What vaccines are included in the Valneva-CSL Seqirus agreement?
The agreement includes Valneva’s chikungunya vaccine IXCHIQ, Japanese Encephalitis vaccine IXIARO, and cholera/ETEC vaccine DUKORAL.
How long will the partnership last?
The partnership between Valneva and CSL Seqirus is set to last for three years.
What are Valneva's sales expectations for 2025?
Valneva expects its product sales to grow to between €170 and €180 million in 2025.
Who can be contacted for media inquiries regarding Valneva?
Laetitia Bachelot-Fontaine handles media inquiries and can be reached at +33 (0)6 4516 7099.
What is Valneva's focus as a company?
Valneva focuses on developing and commercializing prophylactic vaccines for infectious diseases, utilizing a targeted approach to meet unmet medical needs effectively.
